FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943264783> ?p ?o ?g. }

• W2943264783 endingPage "1945" @default.
• W2943264783 startingPage "1935" @default.
• W2943264783 abstract "Aims Rituximab is standard care in a number of lymphoma subtypes, including follicular lymphoma (FL), although many patients are resistant to rituximab, or develop resistance with repeated treatment, and a high proportion relapse. Obinutuzumab is a novel anti‐CD20 monoclonal antibody with improved efficacy over rituximab. It is approved for previously untreated chronic lymphocytic leukaemia (CLL), and for use with bendamustine in patients with rituximab‐relapsed/refractory FL. Methods Using a previously described population pharmacokinetic (PK) model of obinutuzumab in patients with non‐Hodgkin lymphoma and CLL, we conducted an exposure‐response analysis using data from 6 clinical trials in patients with CD20+ B‐cell malignancies (CLL11, GADOLIN, GATHER, GAUDI, GAUGUIN and GAUSS) to describe the PK properties of obinutuzumab, identify covariates influencing exposure, and explore how exposure affects safety, efficacy and pharmacodynamics. Results A 2‐compartment model with linear and time‐dependent clearance described obinutuzumab PK. Disease type and subtype, body weight, baseline tumour size, and sex had the largest effects on PK. Obinutuzumab exposure was not associated with occurrence or severity of adverse events, but higher exposure appeared to be associated with greater efficacy, particularly longer progression‐free survival. However, in multivariate Cox regression analysis, progression‐free survival benefit in the obinutuzumab plus bendamustine arm was independent of exposure. Conclusion The updated population PK model reported here accurately describes the PK of obinutuzumab patients with non‐Hodgkin lymphoma and CLL. The selected obinutuzumab dosing regimen offers clinical benefit in a majority of rituximab‐refractory FL patients treated with bendamustine, irrespective of variability in exposure, whilst minimising adverse events." @default.
• W2943264783 created "2019-05-09" @default.
• W2943264783 creator A5003079347 @default.
• W2943264783 creator A5009963461 @default.
• W2943264783 creator A5020586738 @default.
• W2943264783 creator A5035445472 @default.
• W2943264783 creator A5037583023 @default.
• W2943264783 creator A5041480653 @default.
• W2943264783 creator A5064242763 @default.
• W2943264783 date "2019-07-12" @default.
• W2943264783 modified "2023-10-16" @default.
• W2943264783 title "Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study" @default.
• W2943264783 cites W105671925 @default.
• W2943264783 cites W1540899451 @default.
• W2943264783 cites W1843656222 @default.
• W2943264783 cites W1901679316 @default.
• W2943264783 cites W1945274657 @default.
• W2943264783 cites W1964486259 @default.
• W2943264783 cites W1967716971 @default.
• W2943264783 cites W1970648523 @default.
• W2943264783 cites W1988367968 @default.
• W2943264783 cites W1996452199 @default.
• W2943264783 cites W2003089766 @default.
• W2943264783 cites W2010329820 @default.
• W2943264783 cites W2016532834 @default.
• W2943264783 cites W2040016931 @default.
• W2943264783 cites W2042725832 @default.
• W2943264783 cites W2048773859 @default.
• W2943264783 cites W2059050919 @default.
• W2943264783 cites W2059995755 @default.
• W2943264783 cites W2091057822 @default.
• W2943264783 cites W2097998097 @default.
• W2943264783 cites W2101648653 @default.
• W2943264783 cites W2108131857 @default.
• W2943264783 cites W2120319857 @default.
• W2943264783 cites W2120725688 @default.
• W2943264783 cites W2121227413 @default.
• W2943264783 cites W2121828824 @default.
• W2943264783 cites W2127401827 @default.
• W2943264783 cites W2127749132 @default.
• W2943264783 cites W2143901303 @default.
• W2943264783 cites W2154643481 @default.
• W2943264783 cites W2159982513 @default.
• W2943264783 cites W2163032035 @default.
• W2943264783 cites W2163450464 @default.
• W2943264783 cites W2163790170 @default.
• W2943264783 cites W2169578616 @default.
• W2943264783 cites W2169675402 @default.
• W2943264783 cites W2169822687 @default.
• W2943264783 cites W2207800748 @default.
• W2943264783 cites W2234908256 @default.
• W2943264783 cites W2469109222 @default.
• W2943264783 cites W2559341198 @default.
• W2943264783 cites W2594315832 @default.
• W2943264783 cites W2767041448 @default.
• W2943264783 cites W2771328536 @default.
• W2943264783 cites W2895729920 @default.
• W2943264783 cites W2980125828 @default.
• W2943264783 doi "https://doi.org/10.1111/bcp.13974" @default.
• W2943264783 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6710522" @default.
• W2943264783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31050355" @default.
• W2943264783 hasPublicationYear "2019" @default.
• W2943264783 type Work @default.
• W2943264783 sameAs 2943264783 @default.
• W2943264783 citedByCount "3" @default.
• W2943264783 countsByYear W29432647832021 @default.
• W2943264783 countsByYear W29432647832022 @default.
• W2943264783 crossrefType "journal-article" @default.
• W2943264783 hasAuthorship W2943264783A5003079347 @default.
• W2943264783 hasAuthorship W2943264783A5009963461 @default.
• W2943264783 hasAuthorship W2943264783A5020586738 @default.
• W2943264783 hasAuthorship W2943264783A5035445472 @default.
• W2943264783 hasAuthorship W2943264783A5037583023 @default.
• W2943264783 hasAuthorship W2943264783A5041480653 @default.
• W2943264783 hasAuthorship W2943264783A5064242763 @default.
• W2943264783 hasBestOaLocation W29432647831 @default.
• W2943264783 hasConcept C126322002 @default.
• W2943264783 hasConcept C143998085 @default.
• W2943264783 hasConcept C203014093 @default.
• W2943264783 hasConcept C2777058707 @default.
• W2943264783 hasConcept C2777607594 @default.
• W2943264783 hasConcept C2777938653 @default.
• W2943264783 hasConcept C2778461978 @default.
• W2943264783 hasConcept C2779338263 @default.
• W2943264783 hasConcept C2780653079 @default.
• W2943264783 hasConcept C2781214270 @default.
• W2943264783 hasConcept C2781442060 @default.
• W2943264783 hasConcept C2908647359 @default.
• W2943264783 hasConcept C71924100 @default.
• W2943264783 hasConcept C98274493 @default.
• W2943264783 hasConcept C99454951 @default.
• W2943264783 hasConceptScore W2943264783C126322002 @default.
• W2943264783 hasConceptScore W2943264783C143998085 @default.
• W2943264783 hasConceptScore W2943264783C203014093 @default.
• W2943264783 hasConceptScore W2943264783C2777058707 @default.
• W2943264783 hasConceptScore W2943264783C2777607594 @default.
• W2943264783 hasConceptScore W2943264783C2777938653 @default.
• W2943264783 hasConceptScore W2943264783C2778461978 @default.

• next